Normalization of CSF pTau measurement by Aβ(40) improves its performance as a biomarker of Alzheimer’s disease

BACKGROUND: Alzheimer’s disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between these measurements and their relative ability to predict subsequent disease progression. METHODS: In 219 cognitively unimpaired and 12...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Alzheimers Res Ther
Egile Nagusiak: Guo, Tengfei, Korman, Deniz, La Joie, Renaud, Shaw, Leslie M., Trojanowski, John Q., Jagust, William J., Landau, Susan M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7429887/
https://ncbi.nlm.nih.gov/pubmed/32799929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00665-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak